John Libbey Eurotext




Chemotherapy and renal toxicity
Bulletin du Cancer. Volume 95, Number 8, 96-103, FMC Oncogériatrie, Formation SFC
Résumé Article gratuit
Author(s) : Vincent Launay-Vacher, Corinne Isnard-Bagnis, Nicolas Janus, Svetlana Karie, Gilbert Deray
Summary : Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, methotrexate, and gemcitabine are well-known. The mechanisms of their renal toxicity and the means of its prevention are presented in this article. Anti-angiogenic drugs, recently marketed or still under clinical development, may also interact with the kidneys. In general, optimising the renal tolerance of anticancer drugs requires an appropriate evaluation of patients’renal function, before and during treatment, at each course. Serum creatinine alone is not a reliable index of renal function. Its evaluation must be performed with the use of Cockcroft-Gault or aMDRD formulae. In patients with abnormal renal function, dosage adjustment is often required to improve the renal tolerance, and also to limit the risk of extra-renal toxicities (such as haematological toxicities) induced by a drug overdosage, in those patients with reduced drug-elimination.
Keywords : chemotherapy, platinum salts, methotrexate, gemcitabine, anti-angiogenics, renal toxicity

Chemotherapy and renal toxicity